ATE252151T1 - Apoptosegen von wirbeltieren, zusammensetzungen und verwendungen - Google Patents

Apoptosegen von wirbeltieren, zusammensetzungen und verwendungen

Info

Publication number
ATE252151T1
ATE252151T1 AT94920799T AT94920799T ATE252151T1 AT E252151 T1 ATE252151 T1 AT E252151T1 AT 94920799 T AT94920799 T AT 94920799T AT 94920799 T AT94920799 T AT 94920799T AT E252151 T1 ATE252151 T1 AT E252151T1
Authority
AT
Austria
Prior art keywords
recombinant
compositions
polypeptides
cell death
vertebrate
Prior art date
Application number
AT94920799T
Other languages
English (en)
Inventor
Craig B Thompson
Lawrence H Boise
Gabriel Nunez
Original Assignee
Arch Dev Corp
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arch Dev Corp, Univ Michigan filed Critical Arch Dev Corp
Application granted granted Critical
Publication of ATE252151T1 publication Critical patent/ATE252151T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/465—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from birds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT94920799T 1993-06-22 1994-06-22 Apoptosegen von wirbeltieren, zusammensetzungen und verwendungen ATE252151T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/081,448 US5646008A (en) 1993-06-22 1993-06-22 Vertebrate apoptosis gene: compositions and methods
PCT/US1994/007089 WO1995000642A1 (en) 1993-06-22 1994-06-22 Vertebrate apoptosis gene: compositions and methods

Publications (1)

Publication Number Publication Date
ATE252151T1 true ATE252151T1 (de) 2003-11-15

Family

ID=22164231

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94920799T ATE252151T1 (de) 1993-06-22 1994-06-22 Apoptosegen von wirbeltieren, zusammensetzungen und verwendungen

Country Status (8)

Country Link
US (5) US5646008A (de)
EP (1) EP0706568B1 (de)
JP (1) JP3871339B2 (de)
AT (1) ATE252151T1 (de)
AU (1) AU7177394A (de)
CA (1) CA2165969C (de)
DE (1) DE69433240T2 (de)
WO (1) WO1995000642A1 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001992A (en) * 1999-01-07 1999-12-14 Isis Pharmaceuticals Inc. Antisense modulation of novel anti-apoptotic bcl-2-related proteins
US5646008A (en) * 1993-06-22 1997-07-08 The Regent Of The University Of Michigan Vertebrate apoptosis gene: compositions and methods
US6160106A (en) * 1993-10-12 2000-12-12 Yeda Research & Development Co., Ltd. Tumor suppressor genes, proteins encoded thereby and use of said genes and proteins
ES2256843T3 (es) * 1993-11-30 2006-07-16 Tanox, Inc. Proteinas con que modulan la apoptosis, adn codante para estas proteinas, y su modo de utilizacion.
US5998131A (en) * 1994-10-07 1999-12-07 Lxr Biotechnology, Inc. Screening methods for the identification of compounds capable of abrogating BaK-BHRF-1 protein interactions
JPH1189573A (ja) * 1994-10-14 1999-04-06 Yutaka Shindo アポトーシス関与遺伝子
US5789389A (en) * 1995-03-17 1998-08-04 Board Of Trustees Of University Of Illinois BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs
ATE244305T1 (de) * 1995-05-04 2003-07-15 Us Gov Sec Navy Verfahren zur modulation der t-zell- überlebensrate durch von bcl-xl protein-spiegels
US6143291A (en) * 1995-05-04 2000-11-07 Us Navy Methods for modulating T cell survival by modulating bcl-XL protein level
FR2739561B1 (fr) * 1995-10-06 1997-12-26 Inst Nat Sante Rech Med Utilisation d'un vecteur assurant l'expression ou l'augmentation transitoire de l'activite bc1-2
AUPN727595A0 (en) * 1995-12-22 1996-01-18 Walter And Eliza Hall Institute Of Medical Research, The Therapeutic compositions
GB9600660D0 (en) 1996-01-12 1996-03-13 Ciba Geigy Ag Protein
US5972622A (en) * 1996-02-08 1999-10-26 Desjardins; Louise Method of detecting apoptosis using an anti-human GP46 monoclonal anti-body
EP0886650A1 (de) * 1996-02-14 1998-12-30 Novartis AG Gentherapie von Endothelzellen mit anti-apoptotischen Proteinen zur Bekämpfung von Zuständen, welche mit Entzündungen und Transplantationen einhergehen.
US5789201A (en) * 1996-02-23 1998-08-04 Cocensys, Inc. Genes coding for bcl-y a bcl-2 homologue
AUPN896596A0 (en) 1996-03-27 1996-04-26 Walter And Eliza Hall Institute Of Medical Research, The Therapeutic molecules
AU728863B2 (en) * 1996-03-27 2001-01-18 Walter And Eliza Hall Institute Of Medical Research, The A novel mammalian gene, bcl-w, belongs to the bcl-2 family of apoptosis-controlling genes
US5935801A (en) * 1996-03-29 1999-08-10 Dana-Farber Cancer Institute Monoclonal antibody that detects apoptotic antigen
CA2262696A1 (en) 1996-08-02 1998-02-12 Dana-Farber Cancer Institute Bcl-xy, a novel bcl-x isoform, and uses related thereto
US5776905A (en) * 1996-08-08 1998-07-07 The Board Of Trustees Of The Leland Stamford Junior University Apoptotic regression of intimal vascular lesions
US20020194637A1 (en) * 2001-06-06 2002-12-19 University Of Massachussetts Embryonic or stem-like cell lines produced by cross species nuclear transplantation
US7696404B2 (en) * 1996-08-19 2010-04-13 Advanced Cell Technology, Inc. Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions
US5912168A (en) * 1996-08-30 1999-06-15 Genesis Research & Development Corporation Limited CD95 regulatory gene sequences
WO1999002192A1 (en) * 1997-07-11 1999-01-21 Brandeis University Method of inducing apoptosis by reducing the level of thiamin
US7736898B1 (en) 1997-07-11 2010-06-15 Brandeis University Thiaminases and thiaminase genes for use in apoptotic therapies
US6229066B1 (en) 1997-07-30 2001-05-08 The Curators Of The University Of Missouri Cytokinin oxidase
US6172216B1 (en) 1998-10-07 2001-01-09 Isis Pharmaceuticals Inc. Antisense modulation of BCL-X expression
US6214986B1 (en) * 1998-10-07 2001-04-10 Isis Pharmaceuticals, Inc. Antisense modulation of bcl-x expression
AU760466B2 (en) 1999-02-26 2003-05-15 Johns Hopkins University, The A novel inhibitor of programmed cell death
JP3907863B2 (ja) * 1999-04-08 2007-04-18 独立行政法人科学技術振興機構 アポトーシス抑制又は促進物質のスクリーニング方法
US6346382B1 (en) 1999-06-01 2002-02-12 Vanderbilt University Human carbamyl phosphate synthetase I polymorphism and diagnostic methods related thereto
US9486429B2 (en) 1999-06-01 2016-11-08 Vanderbilt University Therapeutic methods employing nitric oxide precursors
US6737511B1 (en) 1999-08-16 2004-05-18 The United States Of America As Represented By The Department Of Health And Human Services Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis
JP4544715B2 (ja) * 1999-08-17 2010-09-15 成男 太田 ラットｂｃｌ−ｘ遺伝子の改変型ｃＤＮＡと改変型タンパク質
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
US6706766B2 (en) 1999-12-13 2004-03-16 President And Fellows Of Harvard College Small molecules used to increase cell death
JP2003516744A (ja) * 1999-12-14 2003-05-20 ザ バーナム インスティチュート Ｂｃｌ−ｇポリペプチド、それをコードする核酸および使用方法
US7638324B2 (en) 2000-04-06 2009-12-29 Burnham Institute For Medical Research Bcl-G polypeptides, encoding nucleic acids and methods of use
JP3906078B2 (ja) * 1999-12-27 2007-04-18 塩野義製薬株式会社 Ｂｈ４融合ポリペプチド
US20010053769A1 (en) 2000-01-21 2001-12-20 Christiane Ferran Use of pro-apoptotic factors in treatment of atherosclerosis
AU2001282986A1 (en) * 2000-07-26 2002-02-05 University Of Maryland, Baltimore The protein kinase domain of the large subunit of herpes simplex type 2 ribonucleotide reductase (icp10pk) has anti-apoptopic activity
JP5087201B2 (ja) 2000-08-03 2012-12-05 ジョンズ・ホプキンス・ユニバーシティ 抗原に小胞体シャペロンポリペプチドを連結した分子ワクチン
US20060199780A1 (en) * 2000-11-06 2006-09-07 June Carl H Methods for modulating T cell survival by modulating bcl-XL protein level
US7226992B1 (en) * 2000-11-20 2007-06-05 Abbott Laboratories Mutant Bcl-2 proteins and uses thereof
WO2002053701A2 (en) * 2000-12-29 2002-07-11 Vanderbilt University Epididymal lipocalin gene and uses thereof
FR2826869A1 (fr) * 2001-07-04 2003-01-10 Ct Regional De Lutte Contre Le Produits aptes a traiter les cancers de l'ovaire et a en prevenir les rechutes
US7670781B2 (en) 2002-01-03 2010-03-02 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an agent that provides a primary activation signal and another agent that provides a co-stimulatory signal
US7638326B2 (en) 2002-01-03 2009-12-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
AU2003237257A1 (en) 2002-05-24 2003-12-12 Advanced Cell Technology, Inc. A bank of stem cells for transplantation
US20060200871A1 (en) * 2002-10-21 2006-09-07 Van Ness Brian G Transgenic non-human animals with expanded mature b cell and plasma cell populations
JP4564952B2 (ja) * 2003-01-17 2010-10-20 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病の治療および予防のためのジペプチジルペプチダーゼ阻害薬としての３−アミノ−４−フェニルブタン酸誘導体
AU2004210149A1 (en) * 2003-01-31 2004-08-19 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2005047501A1 (en) * 2003-02-24 2005-05-26 Johns Hopkins University Molecular vaccines employing nucleic acid encoding anti-apoptotic proteins
EP1644048B1 (de) * 2003-05-05 2015-04-29 Johns Hopkins University Anti-krebs-dna-vakzine mit einer für plasmide kodierenden signalsequenz, mutiertes onkoprotein-antigen und hitzeschockprotein
US20050069918A1 (en) * 2003-05-29 2005-03-31 Francois Claret JAB1 as a prognostic marker and a therapeutic target for human cancer
DE602004019965D1 (de) * 2003-11-19 2009-04-23 Survac Aps Proteine der bcl-2-familie und fragmente davon, und ihre verwendung bei krebspatienten
WO2005078108A2 (en) * 2004-02-09 2005-08-25 The Samuel Roberts Noble Foundation, Inc. Stress resistant plants
EP2295588B1 (de) 2004-05-27 2018-03-07 The Trustees Of The University Of Pennsylvania Neue künstliches antigen präsentierende zellen und verwendungen dafür
EP2484780A1 (de) 2004-07-23 2012-08-08 The University of North Carolina At Chapel Hill Verfahren und Materialien zur Bestimmung der Schmerzempfindlichkeit und Vorhersage und Behandlung zugehöriger Störungen
WO2006073970A2 (en) * 2005-01-06 2006-07-13 The Johns Hopkins University Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
EP1846026A4 (de) * 2005-01-26 2008-07-02 Univ Johns Hopkins Antikrebs-dna-impfstoff mit plasmiden zur kodierung eines mutierten onkoprotein-antigens und von calreticulin
WO2008024844A2 (en) * 2006-08-22 2008-02-28 The Johns Hopkins University Anticancer combination therapies
US8481023B2 (en) * 2006-09-15 2013-07-09 Ottawa Hospital Research Institute Oncolytic rhabdovirus
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
US20080260765A1 (en) * 2007-03-15 2008-10-23 Johns Hopkins University HPV DNA Vaccines and Methods of Use Thereof
WO2008124133A1 (en) 2007-04-07 2008-10-16 Whitehead Institute For Biomedical Research Reprogramming of somatic cells
US7825143B2 (en) * 2007-07-10 2010-11-02 Montana State University - Billings Method for controlling the yeast-to-filamentous growth transition in fungi
ES2732810T3 (es) * 2008-01-31 2019-11-26 Univ Vanderbilt Procedimientos y composiciones para el tratamiento de hemorragia aneurismática subaracnoidea coronaria y arterial
CA2714272C (en) * 2008-01-31 2016-06-28 Vanderbilt University Therapeutic treatment for lung conditions
US20090285861A1 (en) * 2008-04-17 2009-11-19 Tzyy-Choou Wu Tumor cell-based cancer immunotherapeutic compositions and methods
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (de) 2011-10-27 2013-05-01 Christopher L. Parks Von einem eingehüllten Virus abgeleitete Virenpartikel
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
TW202214844A (zh) 2020-06-17 2022-04-16 美商健生生物科技公司 用於製造多能幹細胞之材料及方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015568A (en) * 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans
US5082774A (en) * 1988-08-30 1992-01-21 The General Hospital Corporation Recombinant human nerve growth factor
JP3454275B2 (ja) * 1992-06-05 2003-10-06 佑 本庶 プログラムされた細胞死に関連した新規なポリペプチドおよびそれをコードするｄｎａ
US5646008A (en) * 1993-06-22 1997-07-08 The Regent Of The University Of Michigan Vertebrate apoptosis gene: compositions and methods

Also Published As

Publication number Publication date
CA2165969A1 (en) 1995-01-05
US6911532B2 (en) 2005-06-28
US20020137182A1 (en) 2002-09-26
EP0706568A1 (de) 1996-04-17
CA2165969C (en) 2010-08-10
US5834309A (en) 1998-11-10
JPH09502603A (ja) 1997-03-18
EP0706568B1 (de) 2003-10-15
AU7177394A (en) 1995-01-17
US6303331B1 (en) 2001-10-16
DE69433240T2 (de) 2004-07-15
JP3871339B2 (ja) 2007-01-24
WO1995000642A1 (en) 1995-01-05
US6395510B1 (en) 2002-05-28
DE69433240D1 (de) 2003-11-20
US5646008A (en) 1997-07-08

Similar Documents

Publication Publication Date Title
ATE252151T1 (de) Apoptosegen von wirbeltieren, zusammensetzungen und verwendungen
DE69230888T2 (de) Somatostatinrezeptoren
ATE286907T1 (de) Cytokinin-designiertes lerk-5
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
DE69334100D1 (de) Elk ligand, ein cytokin
BG100771A (en) Hematopoeic protein and ways and methods for its preparation
IL80451A0 (en) Dna sequences,recombinant dna molecules,processes for producing mis-like polypeptides and pharmaceutical containing said peptides
DE69131580D1 (de) GDF-1 und UOG1 Proteine
ATE215601T1 (de) Rezeptoren der steroid/thyroid superfamilie von rezeptoren
ES2218872T3 (es) Polipeptido 10 de tipo citoquina de mamifero.
DE69839566D1 (de) Chimäre polypeptide, die das fragment b des shigatoxins sowie peptide von therapeutischem interesse enthalten
BR9610133A (pt) Vetor recombinante, organismo hospedeiro gram-positivo, processos para engenheirar um organismo hospedeiro gram-positivo, para mostrar a proteìna ou polipeptìdeo desejado em sua superfìcie, para imobilizar organismo hospedeiro gram-positivo e para triar uma coleção de substâncias, vacina, composição e usos de organismos hospedeiro e da composição.
ATE73492T1 (de) Dns die eine sequenz enthalten die fuer ein kristallprotein oder ein polypeptid mit insektiziden eigenschaften kodiert, mit solcher dns transformierte mikroorganismen und zusammensetzungen die diese kristallproteine, polypeptide oder mikroorganismen enthalt.
KR980002066A (ko) 변이형 인간 성장호르몬 및 그의 용도
WO1994028132A3 (en) Opioid receptors: compositions and methods
IL84700A (en) Hybrid proteins,dnas coding therefor,hybrid vectors containing such dnas and hosts transformed therewith,the preparation of such hybrid proteins and pharmaceutical compositions containing them
DE60039677D1 (de) Akt-3 nukleinsäure, polypeptide und deren verwendung
CA2175476A1 (en) Opioid receptor: compositions and methods
ATE196775T1 (de) Gereinigte flt3 liganden von saeugentieren, agonisten und antagonisten davon
NZ504025A (en) Vitamin D receptor related polypeptides (VDRR) and its use in treating inflammatory disease
AU669149B2 (en) Expression signal-peptide-free staphylokinases
ATE294861T1 (de) Polypeptide mit opioider rezeptor-aktvität, für sie kodierende nukleinsäuren und ihre verwendungen
ATE213773T1 (de) In apoptosis beteiligte cysteine protease cmh-1 und dns-sequenzen dafür
AU5327198A (en) Nucleotide sequence coding for a flavin-containing monooxygenase, corresponding protein and their applications in the fields of diagnosis and therapy
BR0015170A (pt) Proteìnas de hcv com oxirredução reversìvel e conformação similar à nativa

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties